drugset / Trial / NCT01338675

Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)

NCT01338675

Phase 1/2 Unknown 5 enrolled Seoul National University Hospital
NaSingle-groupOpen-labelTreatment

Summary

In this study the investigators plan to use optimal busulfan dose through pharmacokinetic study in stem cell transplantation of CGD patients.

Timeline

Start
2011-01
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Busulfan Small molecule 80 mg/m2 Intravenous
Subject Busulfan Small molecule 120 mg/m2 Intravenous